### National Center for Immunization & Respiratory Diseases



## **Introduction to the HPV Vaccines Work Group**

Oliver Brooks, MD
Chair, HPV Vaccines Work Group

Advisory Committee on Immunization Practices

October 24, 2024

## Background

- HPV Vaccines Work Group re-formation announced at June 2024 ACIP meeting
- An HPV Vaccines Work Group met previously for many years, but had been inactive since 2019
- 3 meetings since July 2024

# **Current HPV vaccination recommendations, United States**

- Routine vaccination
  - Age 11 or 12 years
  - Can be started at age 9 years
- Catch-up vaccination
  - Through age 26 years
- Shared clinical decision-making
  - Age 27–45 years

#### **Number of doses**

2 doses (0, 6-12 months) if starting series before 15<sup>th</sup> birthday

3 doses (0,1-2, 6 months) if starting series on or after 15<sup>th</sup> birthday or if immunocompromising condition

## **Work Group Terms of Reference**

#### Number of doses in the recommended HPV vaccination series

- Accumulating evidence on efficacy of HPV vaccination with fewer doses
- In 2022, the World Health Organization recommended a two-dose schedule for persons aged 9 years or older and, as an off-label option, a single-dose schedule can be used for those aged 9–20 years
- Work Group is reviewing data to inform policy for:
  - two doses for persons aged 15 years and older
  - one dose for persons aged 9 years and older

## **Work Group Terms of Reference**

## Wording of the age for routine HPV vaccination

- Some stakeholders interested in starting vaccination at age 9 years
- Current ACIP recommendations are consistent with vaccination at age 9 years
- Work Group is considering modification of wording to "HPV vaccination is routinely recommended at age 9 to 12 years" to allow more flexibility

## **ACIP HPV Vaccines Work Group progress**

- Reviewed background data on the two issues being considered
- Number of doses in the recommended HPV vaccination series:
  - Started GRADE process
  - Planning full Evidence to Recommendations (EtR) framework and ACIP vote at future meeting
- Wording of the age for routine HPV vaccination:
  - Reviewed related literature
  - Not using GRADE
  - Planning modified EtR and ACIP vote at future meeting

## **ACIP HPV Vaccines Work Group**

#### **ACIP voting members**

Oliver Brooks (chair) Noel Brewer Sybil Cineas

#### **CDC Co-Leads**

Carla DeSisto
Lauri Markowitz

#### **Liaison members**

Robin O'Meara (AAFP) Angela Myers (AAP) Linda Eckert (ACOG) Alfonso Iorio (ACP) Jamilia Sherls (AIM) Sandy Fryhofer (AMA) Sean O'Leary (IDSA) Nicole Forbes (NACI) Kevin Ault (NFID) Alexandra Yonts (PIDS) Nneka Holder (SAHM)

#### **Ex-Officio** members

Sixun Yang (FDA)
Aimée R. Kreimer (NIH)
Eleanore Chuang (NIH)

#### **Consultant members**

Laura Makaroff (ACS)
Peter Szilagyi
Rachel Winer
Elizabeth Moore (consumer rep)

#### **GRADE** consultants

Doug Campos-Outcalt Rebecca Morgan

## **ACIP HPV Vaccines Work Group - CDC Staff**

Julia Gargano (DVD)

Ruth Stefanos (DVD)

Virginia Senkomago (DCPC)

Patrick Clay (DSTDP)

Harrell Chesson (DSTDP)

Shannon Stokley (ISD)

Adefemi Adeleke (ISD)

Cassandra Pingali (ISD)

Elizabeth R. Unger (DHCPP)

Gitika Panicker (DHCPP)

Christine Olson (ISO)

Julianne Gee (ISO)

Hannah Rosenblum (ACIP Secretariat)

# Today's agenda

Introduction to policy consideration: reduced number of doses	<b>Dr. Lauri Markowitz</b> CDC/NCIRD
Introduction to policy consideration: wording of the age for routine vaccination	<b>Dr. Ruth Stefanos</b> CDC/NCIRD
Review of literature on HPV vaccination at ages 9-10 to increase coverage	<b>Dr. Sarah Brewer</b> CDC/NCIRD
Next steps	<b>Dr. Carla DeSisto</b> CDC/NCIRD